Under 10% of individuals who could benefit from obesity jabs such as Wegovy have access to them, states the WHO as it releases its initial advice on the medications.
With in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for increased and just availability to this class of drugs.
According to estimates, over two billion will be living with obesity by 2030 without intervention.
"Our latest guidance affirms that excess weight is a lifelong illness that can be addressed with comprehensive and lifelong treatment," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are key hurdles to widespread access to the jabs that can help people shift significant weight, says the organization.
Skinny Jab Supply Crisis
Even under the current most favorable case, the production of such drugs could only cover approximately 100 million people – less than 10% of those who need them, as stated by the health organization.
The recommendation encourages countries and companies to increase availability, via approaches including licensing agreements.
A patent on a key compound – the primary ingredient of a leading brand – is set to lapse in several nations in 2026.
The Way Weight-Loss Jabs Work
These medications mimick a natural hormone to delay gastric emptying, reduce hunger and enhance feelings of fullness so users reduce food intake.
Patients commonly begin shedding pounds in the initial weeks of beginning the weekly injections.
Research suggests patients may see weight return after a year of stopping the drug, because their normal food cravings return.
To be overweight or obese increases your likelihood for contracting medical conditions, including diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight concerns people in every country and was associated with over three and a half million deaths worldwide in 2024, according to the health agency.
